The thrombolytic paradox.
Thrombolytic drugs do not only stimulate the plasmin system but also induce thrombin activation additionally to the preexisting hypercoagulative state in patients with acute myocardial infarction. Testing the in vitro-derived hypothesis of a plasmin-mediated activation of the contact phase of the coagulation leading to the procoagulant effect, several thrombolytic regimen have been evaluated. Paradoxical thrombin activation (referred to as "thrombolytic paradox") was related to absence of fibrin specificity. Highly fibrin-specific drugs like tenecteplase did not cause additional thrombin activation, while non-fibrin-specific drugs like streptokinase caused a marked additional activation of the contact phase and of thrombin. It could be shown that the thrombolytic paradox was related to the extent of systemic plasmin activation confirming the hypothesis of a plasmin-mediated factor XII/kallikrein system activation as cause of the thrombolytic paradox.
Hoffmeister
H M
HM
Medizinische Klinik, Abteilung Innere Medizin III, Eberhard-Karls-Universität, Tübingen, Germany.
Szabo
S
S
Helber
U
U
Seipel
L
L
D005341:Fibrinolysin / Q000187:drug effects / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D013917:Thrombin / Q000187:drug effects / Q000378:metabolism; D015912:Thrombolytic Therapy / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D013917:Thrombin; D005341:Fibrinolysin